PIPGEN - PhD Project 5: Biomarkers of chronically hyperactivated PI3Kδ in patients with APDS.

PIPGEN - PhD Project 5: Biomarkers of chronically hyperactivated PI3Kδ in patients with APDS.

tres logos amsterdam umc.PNG

RESEARCH PROFILE: First Stage Researcher (R1[1])

APPLICATION DEADLINE: 27 June 2021

EU RESEARCH FRAMEWORK PROGRAME: HORIZON 2020

MARIE SKOLODOWSKA CURIE GRANT AGREEMENT NUMBER: 955534

[1] First Stage Researcher (R1) PhD candidate or equivalent. Early stage researcher with less than 4 years FTE research experience. 

 Recuadro con fechas definitivo.png

PhD Project details

Activated PI3 kinase Delta Syndrome (APDS) is a rare disease previously discovered by the group of Prof Sergey Nejentsev (Angulo et al, Science, 2013). It is caused by mutations that increase PI3 kinase δ activity. APDS patients are immunodeficient and have high risks of bronchiectasis, autoimmune manifestations and lymphomas, suggesting that hyperactivated PI3 kinase δ contributes to the pathogenesis of these disorders. ESR5 will use advanced cell and molecular techniques to characterise immunological consequences of chronically hyperactivated PI3 kinase δ in APDS as well as related common disorders.

Host:  Amstersdam UMC (location VUmc), NL.

Supervisor:  Prof Sergey Nejentsev.

Doctoral programme: Vrije University of Amsterdam (4 Years PhD Program).

Envisioned secondments: University of Cambridge, Inserm.

 

Or, know someone who would be a perfect fit? Let them know!

Teamtailor

Applicant tracking system by Teamtailor